Clinical trials: Hepatocellular Carcinoma(HCC)
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Hepatocellular Carcinoma
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver tumour and is the fourth leading cause of cancer-related death worldwide.
- Trial name
- NCT05359939
- Testing
- 18F-FDGal PET/CT versus 18F-choline PET/CT
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Hepatocellular Carcinoma
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
This is a multicentre randomised 3-arm phase II clinical trial in patients with resectable Hepatocellular Carcinoma (HCC). Sixty patients will be randomized 1:1:1 to 6 weeks of pre-operative therapy with: pembrolizumab…
- Trial name
- PRIMER-1 (NCT05185739)
- Testing
- Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Cohort study to assess the impact of ctDNA detection in the follow-up and management of patients with hepatocellular carcinoma treated by TACE
- Conditions
- Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
- Trial name
- Mona-Lisa (NCT05390112)
- Testing
- DNA
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Rouen
Liver Biopsy
Identification of Liver Tumours Using BIP - Biopsy System
This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP…
- Trial name
- NCT02620228
- Testing
- BIP Biopsy System
- Where
- Finland
- Volunteers
- 26 people
- Sponsor
- Injeq Ltd
Liver Tumour
Waterjet Versus Ultrasound Dissection During Hepatic Transection
Before liver transection patients are allocated to either waterjet or CUSA to divide the liver parenchyma.
- Trial name
- NCT02041065
- Testing
- Waterjet induced dissection, CUSA induced dissection
- Where
- Sweden
- Volunteers
- 84 people
- Sponsor
- Karolinska University Hospital
Progress Free Survival (PFS) and Overall Survival (OS)
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
- Trial name
- NCT04393220
- Testing
- Bevacizumab Injection, Nivolumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
HCC, Early Stage HCC
Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study
In this multi-center, dose-finding study, patients with early stage hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer (BCLC) staging system will be included to receive percutaneous radiofrequency ablation in…
- Trial name
- HORA EST HCC (NCT03437382)
- Testing
- Quirem Medical Holmium-166 radioembolization microspheres
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Primary Hepatocellular Carcinoma
Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Title: Single-center, open clinical study on the efficacy and safety of c-Met/PD-L1 T cell injection in the treatment of primary hepatocellular carcinoma Stage: Phase I clinical trial Purpose: To evaluate the efficacy and safety…
- Trial name
- NCT03672305
- Testing
- c-Met/PD-L1 CAR-T cell injection
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Hepatocellular Cancer
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs to learn whether the drug combination works in treating a specific cancer.
- Trial name
- NCT01775501
- Testing
- Leucovorin, Fluorouracil, Oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Cirrhosis
Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis.
- Trial name
- NCT03407001
- Testing
- Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Hepatitis B Virus
Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication
Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT00769730
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metastatic Hepatocellular Carcinoma, Hepatocellular Carcinoma
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral
Background: Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer. It most often occurs in young people who have no history of liver disease. Unresectable FLC most often does not improve with surgery.
- Trial name
- NCT04025567
- Testing
- vancomycin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma
The objective of this study is to study the safety and tumor response of ACE for large HCC.
- Trial name
- NCT03662841
- Testing
- Ablative chemoembolization (ACE)
- Where
- Hong Kong
- Volunteers
- 11 people
- Sponsor
- Chinese University of Hong Kong
Liver Diseases, Hepatocellular Cancer
Adult-to-Adult Living Donor Transplant Cohort Study
The study is being conducted for the following reasons: 1. To determine the prevalence, course, and predictors of poor Health Related Quality of Life (HRQOL) outcomes associated with living donor donation. 2.
- Conditions
- Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C
- Trial name
- A2ALL-2 (NCT01619475)
- Where
- 9 sites in United States, Canada
- Volunteers
- 1,871 people
- Sponsor
- Arbor Research Collaborative for Health
Hepatocellular Carcinoma (HCC)
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based…
- Trial name
- CHANCE2421 (NCT06876753)
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR…
- Trial name
- NCT05062837
- Testing
- Hepatectomy Combined With Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
- Trial name
- CLeAR (NCT07365839)
- Testing
- Arm 1 cemiplimab, Arm 2 cemiplimab and fianlimab
- Sponsor
- Virginia Commonwealth University
Advanced Liver Cancer
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT05603039
- Testing
- QL1706, QL1604, Bevacizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.